PeptideStack
5.2kquestions
20kanswers
220users

Does SSA issue lot-specific documentation, or a batch certificate?

Asked 16 Jun 2025Modified 11 months agoViewed 17k times
20

I have the report as a PDF with the chromatogram on page two, so I can quote specifics.

I have the document in front of me and I can read the numbers. What I cannot do is interpret them.

I am reasonably comfortable with statistics and completely uncomfortable with chromatography, or vice versa.

Which parts of this are informative and which are decoration?

batch-testing
batch-testing

Testing at the batch or lot level: sampling plans, how many vials from a lot need testing to say anything about the lot, and the difference…

865 questions
coa
coa

Certificates of analysis: what fields a useful one carries, how to tell a real analytical report from a marketing document, batch and lot…

749 questions
vendor-vetting
vendor-vetting

Evaluating a supplier on evidence rather than reputation: testing history across batches, whether certificates are batch-specific, how failures…

436 questions
shareeditfollowflag
OS
askedorla_sheridan14k2716 Jun 2025
2Adding for future readers: the certificate should carry the lot number, not just a batch code. – marta_okonkwo 6 months ago
add a comment

5 Answers

Accepted answer first, then by votes
43

Accepted answer

The practical consequence is that spot-testing one vial from a new supplier is better than assuming they are all the same.

Published segregation failures show that even modern automated processes sometimes produce lots with measurable vial-to-vial variation.

In practice, under AQL sampling plans, testing two vials from a fifty-vial lot gives you an operating characteristic curve that tells you what risks you are accepting.

Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.

The caveat is that sampling is a trade-off between cost and confidence, and neither test nor assumption is cost-free.

The practical summary: a lot number without a sampling statement is a lot number without meaning.

shareimprove this answerflag
GP
answered · acceptedg_paskevicius44k3822 Aug 2025
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
50

To be exact about it, a certificate that reports one test result on one vial extrapolates to claim that all two hundred vials in the lot are identical, which is an assumption worth questioning.

Stratified sampling — testing one vial from the top, one from the middle, and one from the bottom of a shipment — is cheap insurance against segregation.

It helps to be literal here: if the entire lot failed qualification, a retest on a different vial is sometimes done, but reporting a retest result under the same lot number is misleading.

Published data on lot homogeneity from manufacturers who sample multiple vials consistently find variation below the published specifications, suggesting the sampling plans work.

If testing multiple vials, state how many you tested and why you chose those vials.

shareimprove this answerflag
JW
answeredj_wierzbicki45k3813 Sept 2025
4Worth flagging that this changed in 2025, so older answers on the site are out of date. – k_szabo 3 months ago
add a comment
34

Put another way, start from the question: how many vials from this lot do I need to test to claim that the lot meets specification, and the answer depends on both the lot size and the acceptable risk.

Acceptance Sampling by Attributes defines the number of samples you need from a lot to claim a specified quality level at a specified risk — it is in ANSI standard Z1.4.

Stated carefully, the sample size determination requires choosing a confidence level and an acceptable error rate, and the smaller the error rate you want, the larger your sample must be.

One qualification: testing more vials gives better confidence, but at some point the cost outweighs the benefit.

Assume segregation is possible, and design your sampling to catch it if it exists.

shareimprove this answerflag
DK
answeredDr_Sara_Kuusela46k382 Sept 2025
4Thank you — the worked example is what makes this usable. – e_dziedzic 5 months ago
3Related: the same reasoning applies to the counter-ion question. – ilaria_bertone 3 months ago
add a comment
20

The single most misleading statement on a research-grade certificate is a lot number with no statement of how many vials from that lot were tested.

If you have reason to suspect inhomogeneity — different appearance in different vials, or a long or warm shipment — testing more vials is the diagnostic move.

Sampling plans for pharmaceutical manufacturing are defined in ISO 2859 and ANSI Z1.4, and they are based on statistical sampling theory.

The practical summary: a lot number without a sampling statement is a lot number without meaning.

edited 12 Aug 2025 by cake_collapsed — updated for the 2026 guidance change

shareimprove this answerflag
CC
answeredcake_collapsed13k2811 Aug 2025
19

The underlying point is that thermal history during shipping is different for every vial, so a lot that experienced thermal abuse may have internal variation even if it was originally homogeneous.

If the lot was manufactured in multiple batches, testing vials from each batch separately establishes whether batch-to-batch variation is acceptable.

I would treat a "complies with" statement without sampling details as a claim rather than as evidence.

If testing multiple vials, state how many you tested and why you chose those vials.

shareimprove this answerflag
TA
answeredtri_gly_ala48k3831 Jul 2025
5Is there a reason to prefer the second method over the first, other than cost? – claudia_ferrante 8 months ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.